Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Stewart Appelrouth is Director at Aim Immunotech. OQRO lists 3 transactions filed with the SEC under this name, the latest on Dec 4, 2024, each linked to the official Form 4.
Director
Disclosures on record
3
Companies involved
1
2 buys, median −33.3 pts vs S&P 500, beat it 0 of 2 times.
Average −33.3 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Nov 21, 2024 to Dec 4, 2024, measured from the first close after the filing. Past results, not a forecast.
2 purchases disclosed; 0% of the 2 measured at 90 days finished ahead of the index.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Aim ImmunotechAIM
3 disclosures · Nov 2024 – Dec 2024 · 3 bought
Dec 2, 2024Bought~$2.4Kdisclosed Dec 4
DetailsOfficial recordDec 2, 2024Bought~$0disclosed Dec 4
DetailsNov 20, 2024Bought~$16Kdisclosed Nov 21
DetailsOfficial recordAs of the latest filing on , Stewart Appelrouth reported holding 355,509 shares of Aim Immunotech (AIM), worth about $51K at the last close of $0 (Nov 13, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Aim Immunotech AIM | 355,509 | 356K direct | $0 | $51K | Dec 2, 2024 |
Is this Stewart Appelrouth’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Stewart Appelrouth bought shares on the open market in 2016, 2018, 2019, 2021, 2023 and 2024, and has not bought since 2024.
Stewart Appelrouth reported 11 open-market purchases and 0 sales since 2016; purchases in 6 different years, most recently 2024.
| Year | Bought | Sold |
|---|---|---|
| 2024 | $48K4×4 trades | — |
| 2023 | $25K1×1 trade | — |
| 2021 | $25K1×1 trade | — |
| 2019 | $39K1×1 trade | — |
| 2018 | $77K3×3 trades | — |
| 2016 | $35K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Dec 2, 2024, Stewart Appelrouth reported holding 355,509 shares of Aim Immunotech (AIM). At the last close of $0 on Nov 13, 2026, that is about $51K. This is the stake disclosed in filings, not a net worth.
Stewart Appelrouth bought shares on the open market in 2016, 2018, 2019, 2021, 2023 and 2024, and has not bought since 2024.
In SEC filings since 2016: the latest open-market purchase is from 2024; no open-market sale is on record.
Aim Immunotech (AIM), from 2016 to 2024: 11 purchases and 0 sales.
Stewart Appelrouth reported 11 open-market purchases and 0 sales here, 2016 to 2024.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
